“This website has been produced
with the financial support of the Drug
Prevention and Information Programme
of the European Commission.

The contents of this publication
are the sole responsibility of
the EuroHRN and can in no way
be taken to reflect the views
of the European Commission”.

Here we publish EuroHRN reports and information as well as reports from external experts and organisations on harm reduction in Europe.

 

Harm reduction in Europe: coverage and civil society advocacy
This report presents the findings of the EuroHRN civil society audit, an activity aimed at collating existing epidemiological and service coverage data and consulting with experts in order to map key issues for harm reduction in Europe.
This includes coverage of harm reduction interventions, policies and civil society advocacy priorities.

 

 

The European Harm Reduction Network published a survey about drug consumption rooms in Europe.

 

The European Harm Reduction Network published a survey among visitors of drug consumption rooms in Amsterdam and Rotterdam.

Preventing Avoidable Deaths:
Essentials and Recommendations on Opioid Overdose

Overdose is the leading cause of death among People who use Drugs , accounting, in Europe, for more than 3.5% of overall deaths in males under 40 years of age (Eurostst, 2012).

 study report euroHRN II 1
 

Models of Community and Peer-Based Overdose Prevention

This report comprises a comparative analysis of legislation, statistics and public health responses to opioid-related overdose in Scotland, Denmark, Italy, Spain, Estonia and Lithuania, as well as recommendations for adoption of good practice policies including collation of documented best practice.

 models of Community report

Drug Consumption Rooms in Europe –
Models, best practice and challenges

The report highlights the different models of drug consumption rooms in Europe, desrcribes barriers for access, presents best practises and adressess in conclusion the advantages of DCRs for people who use drugs and for the general public.

drug consumption in europe models